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In the past the medical use of opioids has depended on many
factors.1Opioids are essential drugs that need to be safeguarded
by appropriate use.2 Ballantyne and colleagues3 point out that
the WHO analgesic ladder was developed for the treatment of
terminal cancer and that the wider interpretation of this treatment
pathway has led to problems.Many guidelines rely on theWHO
ladder approach for the blanket treatment of cancer pain.4
Advances in treatment and increasing cancer survival have led
to a rise in chronic complications that can cause serious pain.5
In our experience, the widespread use of the WHO ladder for
cancer pain has led to serious opioid based problems in a small
group of patients. Moreover, palliative care doctors have
extended their role in the management of multiple chronic
conditions that can be associated with pain.6 Opioids are the
cornerstone of their therapeutic armamentarium. Lessons learnt
by both pain clinicians and GPs about the WHO ladder need to
be disseminated more widely. This should include oncologists
and palliative care doctors as well as the wider medical
fraternity. The medical duty of all doctors is to prevent hurt and
stop harm, especially when the harm is iatrogenic.
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